INRAE

MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma

Retrieved on: 
Tuesday, March 5, 2024

A total of 70 patients have been enrolled in 5 different centers in France in the randomized controlled Phase 2a PICASSO trial, which started in April 2022.

Key Points: 
  • A total of 70 patients have been enrolled in 5 different centers in France in the randomized controlled Phase 2a PICASSO trial, which started in April 2022.
  • The Company provided MaaT013 drug candidate and placebo and will contribute to the microbiome profiling of patients using its proprietary gutPrint® research engine.
  • The unblinding will be done at Week 27 (W27) to assess the primary endpoint which is safety.
  • Having reached this key recruitment milestone, the first publication will be submitted at the end of 2024 or in the first quarter of 2025.

As a new Core Lab under the Million Microbiomes from Humans Project, MGI empowers INRAE MetaGenoPolis in" Le microbiote français - Le French Gut "project to Propel Metagenomics Research

Retrieved on: 
Tuesday, February 6, 2024

MetaGenoPolis will serve as a platform for processing samples from the project Le French Gut and for other researchers within the Million Microbiomes from Humans Project (MMHP).

Key Points: 
  • MetaGenoPolis will serve as a platform for processing samples from the project Le French Gut and for other researchers within the Million Microbiomes from Humans Project (MMHP).
  • "We are excited about the opportunity to further advance research in metagenomics sequencing," said Dr. Yong Hou, General Manager of MGI Europe and Africa.
  • The agreement underscores the commitment of both MGI and MetaGenoPolis to facilitate innovation in metagenomic research as part of MMHP and the project Le French Gut.
  • "We are delighted to partner with MGI to further our research objectives in MMHP and Le microbiote français - Le French Gut," said Alexandre Cavezza, Executive Director of MetaGenoPolis.

Preventing the Effects of Climate Change: EliTerra®, a Technological Platform Dedicated to Biosolutions That Reduce the Water Needs of Field Crops

Retrieved on: 
Thursday, June 1, 2023

Benoit Poinssot, Research Professor at the UMR Agroecology (INRAE, University of Burgundy, Institut Agro Dijon), explains: "There is not one but many phytosterols.

Key Points: 
  • Benoit Poinssot, Research Professor at the UMR Agroecology (INRAE, University of Burgundy, Institut Agro Dijon), explains: "There is not one but many phytosterols.
  • »
    These natural and sustainable solutions are part of the dynamic of helping agriculture meet the challenge of feeding the world's population despite the effects of climate change.
  • While animals only synthesize one cholesterol, plants produce a large number of them, which are also components of cell membranes.
  • Their presence in the membranes plays a central role in the regulation of their fluidity and thus their permeability.

EQS-News: Carbios will receive grants totaling €54 million from French State via France 2030 and Grand-Est Region

Retrieved on: 
Thursday, June 1, 2023

Carbios selected for €30 million in funding from the French State via France 2030 and €12.5 million from the Grand-Est Region, subject to ratification by the European Commission, for the construction of Carbios' first industrial plant in Longlaville (54).

Key Points: 
  • Carbios selected for €30 million in funding from the French State via France 2030 and €12.5 million from the Grand-Est Region, subject to ratification by the European Commission, for the construction of Carbios' first industrial plant in Longlaville (54).
  • The reference plant in Longlaville in the Grand-Est region will be the world’s first PET biorecycling plant and is due for commissioning in 2025.
  • This funding will enable to continue its research into the optimization and continuous improvement of Carbios’ enzymatic technologies.
  • They have spared no effort, with the constant support of the French State and ADEME, to make this plant a reality.

MGI Empowers the Completion of Nearly 60,000 Samples for The Million Microbiome of Humans Project

Retrieved on: 
Monday, May 15, 2023

Despite a brief interruption by the COVID-19 pandemic, we are delighted to see such a monumental milestone merely four years into the project."

Key Points: 
  • Despite a brief interruption by the COVID-19 pandemic, we are delighted to see such a monumental milestone merely four years into the project."
  • Advances in genome sequencing has enabled researchers to better characterize the composition of the microbiome through identification of unculturable microbes.
  • Besides human microbiome, it is highly applicable in agricultural microbiome studies, environmental microbiome studies, pathogen surveillance and identification, and monitoring of antimicrobial resistance genes.
  • MGISP-960's fully automatic operation design allows DNA extraction of 50,000 samples per year and library preparation of 25,000 samples per year.

SATT Paris-Saclay and Valent BioSciences Sign Joint Agreement to Develop Breakthrough Sustainable Biopesticide Technologies

Retrieved on: 
Tuesday, October 27, 2020

In a first of its kind international partnership, SATT Paris-Saclay, the Technology Transfer Accelerator Office of one of the worlds leading innovation clusters, and Valent BioSciences LLC, the worldwide leader in the development, manufacturing, and commercialization of biorational products, signed a joint agreement to develop breakthrough sustainable biopesticide technologies for agricultural applications.

Key Points: 
  • In a first of its kind international partnership, SATT Paris-Saclay, the Technology Transfer Accelerator Office of one of the worlds leading innovation clusters, and Valent BioSciences LLC, the worldwide leader in the development, manufacturing, and commercialization of biorational products, signed a joint agreement to develop breakthrough sustainable biopesticide technologies for agricultural applications.
  • Valent BioSciences offers deep experience, state-of-the-art manufacturing capabilities, a global distribution network, and a longstanding track record of developing innovative technologies.
  • For its first international collaboration, SATT Paris-Saclay very much looks forward to this partnership with the premier biocontrols company, said Xavier Apolinarski, Chairman of SATT Paris-Saclay.
  • Valent BioSciences shares our vision of supporting sustainable practices for food production now and in the future.